SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Green Plains Inc. (GPRE) (CIK 0001309402) (GPRE) — Jan 2, 2020

Green Plains Inc. (GPRE) (CIK 0001309402)
Date: Jan. 2, 2020 · CIK: 0001309402 · Accession: 0000000000-20-000037

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-235740

Date
January 2, 2020
Author
Todd Becker
Form
UPLOAD
Company
Green Plains Inc. (GPRE) (CIK 0001309402)

Letter

January 2, 2020 Todd Becker Chief Executive Officer Green Plains Inc. 1811 Aksarben Drive Omaha, NE 68106 Re:Green Plains Inc. Registration Statement on Form S-3 Filed December 27, 2019 File No. 333-235740 Dear Mr. Becker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michelle Mapes, Esq.

Show Raw Text
January 2, 2020
Todd Becker
Chief Executive Officer
Green Plains Inc.
1811 Aksarben Drive
Omaha, NE 68106
Re:Green Plains Inc.
Registration Statement on Form S-3
Filed December 27, 2019
File No. 333-235740
Dear Mr. Becker:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michelle Mapes, Esq.